Levobetaxolol

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Levobetaxolol
Levobetaxolol structure.svg
Levobetaxolol-fill.png
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
topical (ophthalmic)
ATC code
  • none
Pharmacokinetic data
Elimination half-life20 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H29NO3
Molar mass307.427 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. It is marketed as a 0.25 or 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon. Levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker).

Indications[edit]

It is indicated for intraocular pressure reduction in patients with open-angle glaucoma or ocular hypertension.[1]

Effect[edit]

Levobetaxolol inhibits the beta-1-adrenergic receptor. When applied topically, it reduces intra-ocular pressure (IOP) by 16-23% depending on time of day and the individual. It also has neuroprotective effects.[1] Levobetaxolol has fewer cardiovascular side effects than other beta blockers.

Contraindications and side effects[edit]

Levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure. The drug has been associated with bradycardia and hypertension.[citation needed]

History[edit]

Levobetaxolol was developed in the 1980s.[1] It was FDA approved in 2000.[2]

References[edit]

  1. ^ a b c Quaranta, Luciano; Turano, Raffaele; Pizzolante, Teodoro (2007). "Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension". Clinical Ophthalmology (Auckland, N.Z.). 1 (2): 93–97. ISSN 1177-5467. PMC 2704505. PMID 19668496.
  2. ^ "Betaxon New FDA Drug Approval | CenterWatch". www.centerwatch.com. Retrieved 11 April 2019.